Certainly, more research is required to unambiguously demonstrate that inhibiting NETosis is an appropriate therapy for treating IBD and to establish the optimal dosage of PAD4-specific inhibitors such as GSK484 without generating associated risks like opportunistic infection. This evidence concerns the gene PADI4 and inflammatory bowel disease.